Zobrazeno 1 - 8
of 8
pro vyhledávání: '"329"'
Autor:
Rohtesh S. Mehta, Gregory P. Kaufman, Elisabet E. Manasanch, Neeraj Saini, Chitra Hosing, Uday R. Popat, Qaiser Bashir, Gabriela Rondon, Elizabeth J. Shpall, Partow Kebriaei, Krina K. Patel, May Daher, Ruby Delgado, Muzaffar H. Qazilbash, Stefan O. Ciurea, Yago Nieto, Issa F. Khouri, Samer A. Srour, Denái R. Milton, Robert Z. Orlowski, Richard E. Champlin, Hans C. Lee
Publikováno v:
Blood. 136:24-25
Introduction The role of upfront autologous stem cell transplantation (ASCT) for multiple myeloma (MM) has evolved over the last three decades, with significant improvements in preparative regimen, supportive care, induction, and maintenance therapy.
Autor:
Tony Reiman, Donna E. Reece, Eshetu G. Atenafu, Martha L Louzada, Christopher P. Venner, Muhammad Aslam, Michael Sebag, Kevin W. Song, Arleigh McCurdy, Richard Leblanc, Esther Masih-Khan, Julie Stakiw, Darrell White, Engin Gul, Rami Kotb, Victor H Jimenez-Zepeda
Publikováno v:
Blood. 134:1886-1886
Lenalidomide in combination with dex (Len + dex) was introduced as treatment for relapsed/refractory myeloma in Canada over a decade ago; more recently, Len has been routinely available as part of first-line therapy, both in transplant-eligible patie
Autor:
Suzanne R. Hayman, Morie A. Gertz, Steven R. Zeldenrust, Francis K. Buadi, Miriam Hobbs, Moritz Binder, Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Wilson I. Gonsalves, Ronald S. Go, Prashant Kapoor, John A. Lust, Robert A. Kyle, Taxiarchis Kourelis, S. Vincent Rajkumar, Rahma Warsame, Amie Fonder, Stephen J. Russell, Nelson Leung, Arjun Lakshman, Lisa Hwa
Publikováno v:
Blood. 132:4497-4497
Background: The introduction of novel therapeutics has led to improved outcomes in patients with multiple myeloma (MM). MM and its precursor lesion smoldering multiple myeloma (SMM) have traditionally been associated with increased mortality despite
Autor:
Maurizio Zangari, Antje Hoering, Jeffery R. Sawyer, Pingping Qu, Bart Barlogie, Joshua Epstein, Christoph Heuck, Erming Tian, Frits van Rhee, Gareth J. Morgan
Publikováno v:
Blood. 126:2982-2982
Introduction In multiple myeloma (MM), deletion of chromosome 17 p13 (del17p) is a poor prognostic feature. The percentage of cells carrying an abnormality has been reported to be important with thresholds of 20% being taken generally but thresholds
Autor:
Pieter Sonneveld, Chrissy H. Y. Van Beurden-Tan, Philippe Moreau, Laura Rosiñol, Walter M Gregory, Michel van Agthoven
Publikováno v:
Blood. 124:2122-2122
INTRODUCTION Multiple Myeloma (MM) is an incurable disease and its treatment is characterized by treatment sequences (treatment lines). We questioned whether a health economic (HE) model could be developed that analyses treatment sequences (TS) rathe
Autor:
Ajay K. Nooka, Jonathan L. Kaufman, Nishi N Shah, Bilal Hassan, Lawrence H. Boise, Ifor Williams, Sagar Lonial
Publikováno v:
Blood. 122:3148-3148
Background Heavy light chain (HLC) assays allow for accurate quantification of involved and uninvolved immunoglobulins (Ig) of the affected isotype. HLC ratio is of particular interest in measuring low level disease where there is limited utility for
Autor:
Kai Neben, Bernard Klein, Uta Bertsch, Dirk Hose, Jérôme Moreaux, Hartmut Goldschmidt, Anna Jauch, Christoph Schultes, Tobias Meiβner, Joe Lewis, Christof von Kalle, Jens Hillengass, Jürgen Zimmermann, Jean François Rossi, Vladimir Benes, Thomas Möhler, Anja Seckinger, Blanka Rebacz
Publikováno v:
Blood. 114:2856-2856
Abstract 2856 Poster Board II-832 BACKGROUND. Molecular profiling of multiple myeloma allows the identification of novel targets, including HIF1A, and evaluation of their expression within large cohorts of patients. We report here the expression of H
Autor:
James R. Berenson, Robert Vescio, Sonia Gauron, Horst Schran, Regina A. Swift, Jannick Denouel, Pierre Major, Christina Rivera, Sanela Bilic
Publikováno v:
Blood. 106:5192-5192
BACKGROUND: Zoledronic acid has demonstrated efficacy and safety in the treatment of bone lesions in patients with multiple myeloma. However, bisphosphonates are known to have dose-dependent and infusion rate-dependent effects on renal function and p